Trials / Completed
CompletedNCT05265988
Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib
Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib Upon Progression to Chemotherapy and Next Generation Hormonal Agents: a Phase II Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Alfredo Berruti · Academic / Other
- Sex
- Male
- Age
- —
- Healthy volunteers
- Accepted
Summary
Multiparametric assesment of bone response in mCRPC patients treated with Cabozantinib upon progression to chemotherapy and next generation hormonal agents: a phase II study
Detailed description
This is a monocentric, single arm, prospective clinical trial designed to obtain explorative information about the effect of Cabozantinib on bone in prostate cancer patients with bone metastatic castration resistant disease, previously treated with two taxanes and at least one next generation hormonal agent. Activity of bone metastatic disease will be assessed by WB-DW-MRI, while changes in bone metabolism will be studied through DXA scan and soluble biomarkers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabozantinib | Cabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy |
Timeline
- Start date
- 2021-11-29
- Primary completion
- 2024-06-29
- Completion
- 2024-06-29
- First posted
- 2022-03-04
- Last updated
- 2024-07-31
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT05265988. Inclusion in this directory is not an endorsement.